References
- Portman DJ, Gass ML;Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Climacteric 2014;17:557–63
- Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014;17:3–9
- Nappi RE, Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric 2012;15:36–44
- Nappi R, Palacios S, Panay N, Rabe T, Krychman M, Particco M. Results of the European REVIVE (REal Women’s VIew of Treatment Options for Menopausal Vulvar/Vaginal ChangEs) survey. Presented at the 10th Congress of the European Menopause and Andropause Society, Madrid, May 2015, Abst 254
- Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281: 537–44
- Bachmann GA, Notelovitz M, Kelly SJ, et al. Long-term non- hormonal treatment of vaginal dryness. Clin Pract Sex 1992;8:12
- Palacios S. The vulval health index. Personal communication, 2015
- Erekson EA, Yip SO, Wedderburn TS, et al. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause 2013;20:973–9
- Huang AJ, Gregorich SE, Kuppermann M, et al. Day-to-Day Impact of Vaginal Aging questionnaire: a multidimensional measure of the impact of vaginal symptoms on functioning and well-being in postmenopausal women. Menopause 2015;22:144–54
- Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, de Villiers TJ, Simon JA. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2015;18:233–40
- Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
- NAMS Position Statement. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902
- Gambacciani M, Levancini M, Cervigni M. Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric 2015;18:757–63
- Labrie F, Archer DF, Bouchard C, et al.; Members of the VVA Prasterone Group. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 2015;81:46–56
- Palacios S, Mejia A, Neyro JL. Treatment of the genitourinary syndrome of menopause. Climacteric 2015;18(Suppl 1):22–8